South & Central America Infectious Disease In vitro Diagnostics Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis

The South & Central America Infectious Disease In Vitro Diagnostics Market is projected to grow significantly, reaching an estimated US$ 2,676.5 million by 2031, up from US$ 2,092.8 million in 2024. This growth represents a compound annual growth rate (CAGR) of 3.6% from 2025 to 2031. The market's expansion is driven by several key factors, including a rising incidence of infectious diseases, increased healthcare spending, and the rapid development of healthcare infrastructure across the region.

Brazil and Argentina are identified as the primary markets for in vitro diagnostics (IVD) in infectious diseases, largely due to their proactive approaches in enhancing diagnostic capabilities and integrating advanced medical technologies. The region is also witnessing a surge in medical tourism, which is amplifying the demand for reliable and rapid diagnostic methods. This trend allows hospitals to offer high-quality patient care, further stimulating market growth. Government initiatives aimed at strengthening health systems, along with improved disease detection methods, are providing additional support to the market.

The South & Central America Infectious Disease IVD market is segmented by application into categories such as HIV/AIDS, Tuberculosis, Hepatitis B and C, Malaria, and others. Notably, Hepatitis B and C are expected to dominate the market share in 2024. Additionally, the market is segmented by end-user, with hospitals and clinics holding the largest share in the same year.

Technological advancements are playing a crucial role in the evolution of the IVD market. Innovations in molecular diagnostics and automation systems are enhancing the accuracy, speed, and accessibility of infectious disease detection. For instance, in June 2024, MP Biomedicals launched a new series of rapid immunochromatographic assays for detecting Helicobacter pylori, Salmonella typhi, and Vibrio cholerae, specifically designed for point-of-care use in resource-limited settings. Furthermore, Sherlock Biosciences began clinical trials for a CRISPR-based over-the-counter test for gonorrhea and chlamydia, aiming for a 2025 launch. Another notable advancement is APEX-TB, which utilizes machine learning and nanotechnology to provide accurate, real-time molecular diagnostics through portable devices. These developments reflect a broader trend towards decentralized, user-friendly, and rapid diagnostic technologies that are shaping the future of infectious disease management.

Country-wise, the market is primarily segmented into Brazil, Argentina, and the rest of South & Central America, with Brazil leading the market in 2024. The Brazilian landscape for infectious disease diagnostics is significantly influenced by the presence of major international companies such as Roche, Abbott, Danaher (Cepheid), Siemens Healthineers, Thermo Fisher, Becton Dickinson, and bioMérieux, alongside strong local players like Fleury, DASA, and Grupo Pardini. These companies have been instrumental in driving market growth, particularly through the introduction of rapid COVID-19 diagnostic solutions, such as Siemens' 15-minute antigen test launched in March 2021.

The GeneXpert platform from Cepheid has gained widespread adoption across Latin America, providing automated, cartridge-based PCR testing for diseases like tuberculosis and SARS-CoV-2. In 2022, Seegene received CE-IVD certification for its Allplex SARS-CoV-2 MDx assay, facilitating its integration into large-scale public infrastructures, including airports and educational institutions. The Brazilian government has also played a pivotal role in market advancement by expediting emergency authorizations through ANVISA and streamlining regulatory processes, which have encouraged a shift from centralized laboratory testing to point-of-care diagnostics. This shift has increased the demand for molecular and rapid antigen testing solutions.

Market consolidation is becoming more pronounced, with strategic acquisitions such as Roche's acquisition of GenMark and Thermo Fisher's purchase of GE's IVD division. Additionally, public-private partnerships are enhancing diagnostic accessibility and fostering innovation in testing platforms throughout Brazil.

Key players in the South & Central America Infectious Disease IVD market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sysmex Corp, bioMerieux SA, Bio-Rad Laboratories Inc, QIAGEN NV, Bruker Corp, QuidelOrtho Corp, Becton, Dickinson and Co, and Danaher Corp. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to deliver innovative products and increase their market share.